General Information of the Drug (ID: M6APDG01674)
Name
Z-Arg-Leu-Val-Agly-Val-Ala-NH2
Status
Investigative
Structure
3D MOL
Formula
C34H57N11O8
InChI
1S/C34H57N11O8/c1-18(2)16-24(40-28(47)23(14-11-15-38-32(36)37)41-34(52)53-17-22-12-9-8-10-13-22)29(48)42-26(20(5)6)31(50)44-45-33(51)43-25(19(3)4)30(49)39-21(7)27(35)46/h8-10,12-13,18-21,23-26H,11,14-17H2,1-7H3,(H2,35,46)(H,39,49)(H,40,47)(H,41,52)(H,42,48)(H,44,50)(H4,36,37,38)(H2,43,45,51)
InChIKey
OILQRSUIXCAKPE-UHFFFAOYSA-N
PubChem CID
44355111
TTD Drug ID
D0N7BP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cathepsin B (CTSB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Cathepsin B (CTSB) is a therapeutic target for Z-Arg-Leu-Val-Agly-Val-Ala-NH2. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Z-Arg-Leu-Val-Agly-Val-Ala-NH2 through regulating the expression of Cathepsin B (CTSB). [1], [2]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?. Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. doi: 10.1016/j.bmcl.2005.10.108. Epub 2005 Nov 15.